DARA has many positives going for it prior to its earnings report. Downside is minimal since it's at book and short interest is at an all time low. The company is basically 2 years old and cannot be judged by its charts past that. Sustained earnings this next quarter will set the pace for the future. <rambo>
Here is another: This equiry is a complete lame duck or the group that thinks they know what they are doing is in major trouble (they don't know yet....)
Who could they sell too? Other than the maker? And marker gonna hold his $basis for month? Elementary!
I think they exited bc 12 % In a day. I will say this one last time the co Dara is so cheap bc it's known as a dilution machine. The markets along with shorts feel confident they can trade this stock to death. Eventually the market will and always does realize and correct to the proper market cap. I believe right now the market cap should be much higher why aren't we higher simply put mostly managements fault. It's managements fault for the constant past dilution. We have seen the revenues pick up and as with lots stocks in bio the sales takes time to develop. but, It's managements fault the co website was never updated for 6 plus months, It's managements fault ir dept is a joke and a dilutive factor bc its non existent, It's managements fault for not buying at least 50k shares in the open market even 25k. I know some guys would think twice before selling if they knew management had skin on this stock but more importantly if management had 100k shares perhaps the lack of proper oversight trust me would not be so non effective. There are positives in fact to many positives for starters a partner will make the markets price krn5500 with orphan status on n pain lets assume 200k patients at 2k a pop or proper treatment course krn5500 is capable of revenues of 400k on n pain alone then throw in mm and really have fun. Int enuf velcade by millennium pharma and celgene are a nice fit why bc mm drugs marketed and sold by these two giants 70% of patients develop n pain disorder. If krn5500 works on mm items a huge market lets not forget puma and its 300$ gain in a single day. Here are some links that will help you dd. http://www.velcade.com/Support-and-resources/Tools-and-downloads?utm_medium=cpc&utm_campaign=search%20%7c%20branded&utm_source=bing&utm_keyword=&utm_content=velcade%20%7c%20multiple%20myeloma%20%7C%20velcade%ae%20%28bortezomib%29_download%20free%20tools%20and%20resources%20for%20your%20journey%2e&utm_term=velcade%20and%20multiple%20myeloma. Note from krn5500"This second orphan drug designation for our key development asset KRN5500 allows us to approach the actual treatment of multiple myeloma, whereas the CCIPN designation is specific to neuropathy. It is noteworthy in this regard that up to 20% of myeloma patients have intrinsic peripheral neuropathy, an incidence that increases to the range of 75% in patients treated with neurotoxic drugs such as thalidomide or bortezomib. We believe this myeloma-specific orphan designation enhances both the viability and the future market opportunity for this valuable pipeline product," said David J. Drutz, M.D., Chief Executive Officer and Chief Medical Officer of DARA BioSciences. That's millennium and celgene. Velcade seems to be like a platform and newer drug, tekeda pharma a sub of millennium just got approval last week for other treatment so platform http://www.takeda.com/ see latest FDA news, see it!
News 
Market Data 
Discover 
